F-star

InvoX Pharma’s F-star Announces Licence Agreement With Takeda for Second Novel Next-Generation Immuno-Oncology Bispecific Antibody

Retrieved on: 
Wednesday, March 22, 2023

InvoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that F-star, an invoX company, has entered into a second licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.

Key Points: 
  • InvoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that F-star, an invoX company, has entered into a second licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
  • Under the terms of the licence agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing licence to research, develop, and commercialize a bispecific antibody directed towards an undisclosed immuno-oncology target using F-star’s proprietary Fcab™ and mAb2™ platforms.
  • This licence agreement represents the second option that Takeda has exercised under an evaluation and licence agreement with F-star that was entered into in July 2021.
  • F-star and Takeda entered into a licence agreement for a different bispecific antibody in July 2022.

F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, August 11, 2022

Second Quarter 2022 Financial Summary:

Key Points: 
  • Second Quarter 2022 Financial Summary:
    Cash and cash equivalents were $53.0 million as of June 30, 2022, compared to $78.5 million at December 31, 2021.
  • R&D expenses were $8.7 million for the quarter ended June 30, 2022, compared to $8.3 million for the corresponding quarter in 2021.
  • G&A expenses were $7.5 million for the quarter ended June 30, 2022, compared to $6.5 million for the second quarter 2021.
  • F-star will not be hosting a conference call to discuss Q2 2022 financial results or corporate update in light of the pending transaction with invoX Pharma announced on June 23, 2022.

STipe Therapeutics appoints Dr Richard Sainson as Chief Scientific Officer to Lead Research and Discovery

Retrieved on: 
Tuesday, May 31, 2022

He will be based in Aarhus, Denmark and report to Dr Claus Olesen, STipes Chief Executive Officer (CEO).

Key Points: 
  • He will be based in Aarhus, Denmark and report to Dr Claus Olesen, STipes Chief Executive Officer (CEO).
  • As CSO, Dr Sainson will lead the research and advancement of the Companys innovative science and platform technology.
  • I look forward to applying my experience and expertise to harness these strengths and to addressing the unmet needs of patients.
  • Richard Sainson has over 20 years of oncology research experience acquired both in academia and industry.

F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 12, 2021

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces second quarter 2021 financial results and provides a corporate update.

Key Points: 
  • CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces second quarter 2021 financial results and provides a corporate update.
  • At the end of the second quarter the company had over $80 million in cash and cash equivalents.
  • Research & Development (R&D) expenses were $8.4 million for the quarter ended June 30, 2021, compared to $2.1 million for the corresponding quarter in 2020.
  • General & Administrative (G&A) expenses were $6.5 million for the quarter ended June 30, 2021, compared to $3.2 million for the second quarter of 2020.

F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA

Retrieved on: 
Wednesday, August 4, 2021

Under the terms of the agreement, MSD will supply KEYTRUDA for a combination arm that will be included in theadaptive Phase 1 clinical protocol of FS120, sponsored by F-star,thatwas initiatedin December of 2020.

Key Points: 
  • Under the terms of the agreement, MSD will supply KEYTRUDA for a combination arm that will be included in theadaptive Phase 1 clinical protocol of FS120, sponsored by F-star,thatwas initiatedin December of 2020.
  • FS120 is currently being exploredas a monotherapy in dose escalation (NCT04648202) , including the evaluation of pharmacokinetics and pharmacodynamics in patients with advanced cancer.
  • FS120 will also be evaluated in combination withKEYTRUDA,with the potential for early demonstration of clinical activity in specifictumorsubtypes.
  • In preclinical studies, FS120 has demonstrated strong additive effects in combination with PD-1 monoclonal antibodies.

F-star Therapeutics to Announce Second Quarter Results and Host Conference Call on August 12, 2021

Retrieved on: 
Monday, August 2, 2021

The Company will host an investor conference call and webcast that same day at 9:00 a.m. EST to discuss financial results and provide a corporate update.

Key Points: 
  • The Company will host an investor conference call and webcast that same day at 9:00 a.m. EST to discuss financial results and provide a corporate update.
  • To access the call, participants may join via a live webcast on the Investors and News section of the F-star Therapeutics website, under Events and Presentations .
  • A replay of the conference call will be available for 90 days from the call and may be accessed in the Investors & News/ Events and Presentations section on the F-star Therapeutics website.
  • Through its proprietary tetravalent, bispecific natural antibody (mAb) format, F-stars mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.

F-star Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Friday, July 9, 2021

Fireside chat with F-star CEO, Eliot Forster

Key Points: 
  • Fireside chat with F-star CEO, Eliot Forster
    Management will be available for 1:1 meetings Tuesday, July 13th
    Neil Brewis, CSO, will speak on a panel discussing Moving Beyond Monoclonals: The Potential of Multispecific Therapies.
  • Management will be available for 1:1 meetings Wednesday, July 14th
    F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm shift in cancer therapy.
  • By developing medicines that seek to block tumor immune evasion, the Companys goal is to offer patients greater and more durable benefits than current immuno-oncology treatments.
  • Through its proprietary tetravalent, bispecific natural antibody (mAb) format, F-stars mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.

Inivata Announces Collaboration with F-star Therapeutics for the use of RaDaRTM Assay

Retrieved on: 
Tuesday, May 25, 2021

Peter Collins, CBO of Inivata, said: This collaboration with F-star underlines the broad potential utility of our RaDaR technology.

Key Points: 
  • Peter Collins, CBO of Inivata, said: This collaboration with F-star underlines the broad potential utility of our RaDaR technology.
  • We are excited to be working with F-star to support the clinical development of their highly innovative bispecific antibodies.
  • Inivata has also launched the personalized RaDaRTM assay allowing the highly sensitive detection of residual disease and recurrence which has been granted Breakthrough Device Designation by the US FDA.
  • Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late-stage cancer development programs.

F-star Therapeutics to Announce First Quarter Results and Corporate Update Call on May 17, 2021

Retrieved on: 
Monday, May 10, 2021

b'CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that it will host an investor conference call and webcast on Monday, May 17, 2021 at 9:00 a.m. EST to discuss financial results for the quarter ending March 31, 2021 and provide a corporate update.\nTo access the call, participants may join via a live webcast on the Investors and News section of the F-star Therapeutics website, under Events and Presentations .

Key Points: 
  • b'CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that it will host an investor conference call and webcast on Monday, May 17, 2021 at 9:00 a.m. EST to discuss financial results for the quarter ending March 31, 2021 and provide a corporate update.\nTo access the call, participants may join via a live webcast on the Investors and News section of the F-star Therapeutics website, under Events and Presentations .
  • By developing medicines that seek to block tumor immune evasion, the Company\xe2\x80\x99s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments.
  • Through its proprietary tetravalent, bispecific natural antibody (mAb\xc2\xb2\xe2\x84\xa2) format, F-star\xe2\x80\x99s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.
  • For more information visit https://www.f-star.com/ and follow us on LinkedIn and Twitter .\n'

F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster

Retrieved on: 
Saturday, April 10, 2021

Neil Brewis, Chief Scientific Officer at F-star Therapeutics, said: We are encouraged by the results of these latest preclinical studies of FS222, our tetravalent bispecific antibody targeting PD-L1 and CD137.

Key Points: 
  • Neil Brewis, Chief Scientific Officer at F-star Therapeutics, said: We are encouraged by the results of these latest preclinical studies of FS222, our tetravalent bispecific antibody targeting PD-L1 and CD137.
  • The early onset of activity and T cell proliferation gives us confidence that FS222 will allow for a wide range of treatment options.
  • Tetravalent binding by FS222 demonstrated optimal activity in multiple preclinical pharmacology studies, outperforming classic heterodimeric bispecific antibodies.
  • Forward-looking statements included in this communication are based on information available to F-star as of the date of this communication.